Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

0.5500 +0.0400 (+7.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
NASDAQ:VRCA Long Term Investor Alert: Investigation over Possible Wrongdoing at Verrica Pharmaceuticals Inc.
San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Verrica Pharmaceuticals Inc. 
Via SBWire
Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Verrica Pharmaceuticals Inc. (VRCA) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
VERRICA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
VRCA DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Verrica Pharmaceuticals Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Wells Fargo & Company Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - WFC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Verrica Pharmaceuticals Inc. Investor News: Robbins LLP is Investigating Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
NASDAQ:VRCA Investor Notice: Lawsuit Alleges Misleading Statements by Verrica Pharmaceuticals Inc.
San Diego, CA -- (SBWIRE) -- 06/21/2022 -- An investor, who purchased NASDAQ:VRCA shares, filed a lawsuit against Verrica Pharmaceuticals Inc over alleged violations of Federal Securities Laws. 
Via SBWire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VRCA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Verrica Pharmaceuticals, Inc. (VRCA) Investors and Encourages Investors to Contact the Firm Before August 5, 2022
From Kirby McInerney LLP
Via Business Wire
VRCA Investor Update: Robbins LLP Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. (VRCA)
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
From Glancy Prongay & Murray LLP
Via Business Wire
Stockholder Alert: Robbins LLP Informs Investors of Class Action Against Verrica Pharmacuticals Inc. (VRCA)
From Robbins LLP
Via Business Wire
VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders
From Robbins LLP
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.